Regeneron Pharmaceuticals (REGN) – Analysts’ Weekly Ratings Changes

Regeneron Pharmaceuticals (NASDAQ: REGN) recently received a number of ratings updates from brokerages and research firms:

• 7/9/2026 – Regeneron Pharmaceuticals had its price target lowered by Piper Sandler from $855.00 to $854.00. They now have an “overweight” rating on the stock.
• 7/8/2026 – Regeneron Pharmaceuticals had its price target lowered by Morgan Stanley from $788.00 to $730.00. They now have an “equal weight” rating on the stock.
• 7/7/2026 – Regeneron Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $707.00 to $696.00. They now have a “sector perform” rating on the stock.
• 7/7/2026 – Regeneron Pharmaceuticals was upgraded by Benchmark Co. from “hold” to “buy”. They now have a $185.00 price target on the stock.
• 7/7/2026 – Regeneron Pharmaceuticals had its price target lowered by Truist Financial Corporation from $778.00 to $769.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Regeneron Pharmaceuticals had its price target lowered by HSBC Holdings plc from $990.00 to $880.00. They now have a “buy” rating on the stock.
• 7/6/2026 – Regeneron Pharmaceuticals had its price target lowered by Cantor Fitzgerald from $785.00 to $750.00. They now have an “overweight” rating on the stock.
• 7/4/2026 – Regeneron Pharmaceuticals was downgraded by Wall Street Zen from “buy” to “hold”.
• 6/24/2026 – Regeneron Pharmaceuticals had its “hold (c)” rating reaffirmed by Weiss Ratings.
• 5/19/2026 – Regeneron Pharmaceuticals had its price target lowered by Canaccord Genuity Group Inc. from $1,057.00 to $875.00. They now have a “buy” rating on the stock.
• 5/18/2026 – Regeneron Pharmaceuticals had its price target lowered by BMO Capital Markets from $900.00 to $730.00. They now have an “outperform” rating on the stock.
• 5/18/2026 – Regeneron Pharmaceuticals had its price target lowered by Truist Financial Corporation from $796.00 to $778.00. They now have a “buy” rating on the stock.
• 5/18/2026 – Regeneron Pharmaceuticals had its price target lowered by JPMorgan Chase & Co. from $950.00 to $850.00. They now have an “overweight” rating on the stock.
• 5/18/2026 – Regeneron Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $762.00 to $707.00. They now have a “sector perform” rating on the stock.
• 5/18/2026 – Regeneron Pharmaceuticals had its price target lowered by Wells Fargo & Company from $800.00 to $700.00. They now have an “equal weight” rating on the stock.
• 5/18/2026 – Regeneron Pharmaceuticals had its price target lowered by Piper Sandler from $875.00 to $855.00. They now have an “overweight” rating on the stock.
• 5/18/2026 – Regeneron Pharmaceuticals was downgraded by Citigroup Inc. from “buy” to “neutral”. They now have a $700.00 price target on the stock, down from $900.00.
• 5/18/2026 – Regeneron Pharmaceuticals had its “market perform” rating reaffirmed by Leerink Partners. They now have a $641.00 price target on the stock, down from $792.00.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were issued a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend was Wednesday, May 20th. Regeneron Pharmaceuticals’s payout ratio is presently 9.16%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This trade represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.